354
Participants
Start Date
September 30, 1998
Primary Completion Date
September 30, 1998
Study Completion Date
November 30, 2003
Ara-C
"* Intermediate dose during induction phase to remission.~* High-dose during consolidation phase in patients with favorable cytogenetics."
Autologous transplantation
"* In patients with normal karyotype and one cycle of chemotherapy to achieve complete remission.~* In patients with other cytogenetics without HLA-Identical sibling."
Allogeneic HLA-identical sibling transplantation
"* Patients without favorable or normal karyotype(and one course to CR).~* Patients with normal karyotype who need two cycles of chemotherapy to achieve CR, and other cytogenetics."
CD34+ selection
In allotransplants, it is performed a CD34+ cell selection of peripheral blood stem cell transplantation.
Hospital A Coruña, A Coruña
Hopital Universitari de Girona Dr. Josep Trueta, Girona
Hospital Universitari Arnau de Vilanova, Lleida
Hospital Universitario Virgen de la Victoria, Málaga
Hospital General Universitario de Murcia, Murcia
Hospital Universitario Rio Hortega, Valladolid
Hospital Universitari Joan XXIII, Tarragona
Hospital Verge de la Cinta, Tortosa
Hospital Clínico Universitario de Valencia, Valencia
Hospital Germans Trias i Pujol, Badalona
Hospital del Mar, Barcelona
Centro Medico Teknon, Barcelona
Hospital de la Santa Creu i Sant Pau, Barcelona
Hospital Vall d'Hebron, Barcelona
Jordi Esteve, Barcelona
ICO Hospital Universitari de Bellvitge, L'Hospitalet Del Llobregat
Hospital Universitari Son Espases, Palma de Mallorca
Joan Bargay, Palma de Mallorca
Mutua de Terrassa, Terrassa
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
OTHER